Oncolytic Virus Immunotherapy Market Size is Predicted to Hit US$ 2.4 Billion by 2030

The oncolytic virus immunotherapy market reached value at US$ 108 Million in 2020 and predicted to hit US$ 2.4 billion by 2030 with expanding CAGR of 32% from 2021 to 2030.

The market growth can be primarily attributed to rising prevalence of cancer worldwide, research and development activities, technological advancements, and increasing collaborations between market players and research institutes.

Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/38191

Oncolytic immunotherapy is a research area of cancer immunotherapy investigating the use of modified viruses to target cancer cells. Currently, a range of genetic modifications is being investigated for the treatment of cancer. It is a novel approach to anticancer therapy; however, the potential of viruses to induce an antitumor immune response has been known for some time.

The global oncolytic virus immunotherapy market is expanding, owing to increase in adoption of newer therapies. This is fueling demand for advanced products. It also represents new business development opportunities. Adenoviruses, herpes viruses, measles viruses, coxsackie viruses, polioviruses, reoviruses, poxviruses, and Newcastle disease viruses are some oncolytic viruses under preclinical and clinical development for cancer therapy.

Scope of The Report

Focus on Spreading Awareness about Cancer to Drive Oncolytic Virus Immunotherapy Market

The increase in cancer incidence across the globe is a major factor driving the demand for cancer treatment among patients. The burden of cancer prevalence is anticipated to lead to initiatives by governments and companies to spread awareness about rapid diagnosis and treatment of different cancer types. GI Cancers Alliance is an organization that engages in boosting awareness & screening, access to quality medical treatments, and helping member organizations collaborate, innovate, and leverage the full potential of effectuating change for cancer patients.

Limitations of Oncolytic Virus Therapy to Hamper Oncolytic Virus Immunotherapy Market

A number of oncolytic viruses are currently under clinical development. Each oncolytic virus carries the characteristics of the parental wild type virus, not only the advantages, but also the disadvantages. One major concern of oncolytic virus therapy has been that the efficacy may be diminished by the presence of circulating antibodies. Moreover, relative poor intratumoral penetration by the oncolytic viruses, which were modified to have a reduced replicative potential, is one of the major limitations of oncolytic virus. This hampers the growth of market.

Research and Development Activities Likely to Gain Considerable Traction

The oncolytic virus immunotherapy is anticipated to revolutionize the future of cancer treatment. A number of oncolytic virus immunotherapies are in the development phase and likely to hit the oncolytic virus immunotherapy market over the course of the forecast period. Translational and clinical efforts that leverage the findings of research and development activities to curate effective oncolytic virus immunotherapies for cancer patients have gained worldwide popularity in the past few years– a factor that is expected to propel market growth during the assessment period. A number of oncolytic virus platforms are being evaluated in clinical trials, including Adenovirus, Piconavirus, Maraba virus, Reovirus, and Vaccinia virus, among others. While the evaluation of these oncolytic virus platforms continues, the development of new platforms and approaches continues to take shape and offer promise due to which, the prospects of the global oncolytic virus immunotherapy market look bright in the upcoming years. Researchers are also exploring the potential of effective combination immunotherapy by utilizing oncolytic viruses to accurately delivery of chimeric antigen receptor (CAR) targets to solid tumor.

Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/38191

Report Highlights

• In terms of type, the global oncolytic virus immunotherapy market has been classified into herpes simplex virus (HSV), vaccinia virus, adenovirus, reovirus, and others. Adenovirus is the most promising agent used in gene-targeted oncolytic virus therapy (GTOVT) due to several good characteristics. Adenovirus is able to infect and kill cancer cells with no harm to normal cells. Moreover, the anti-cancer immune response elicited by the oncolytic adenovirus expands its anti-cancer efficacy, including the metastasis side. This, in turn, increases the use of adenovirus in oncolytic therapy, which drives the segment.
• Based on route of administration, the global oncolytic virus immunotherapy market has been bifurcated into intratumoral and intravenous. The intratumoral segment is driven by increase in use of intratumoral route of administration. Advantages of intratumoral route such as maintenance of the concentration of oncolytic virus at the target site is anticipated to fuel the growth of the segment.
• In terms of application, the global oncolytic virus immunotherapy market has been divided into melanoma, non-small cell lung cancer (NSCLC), pancreatic cancer, breast cancer, and others. The others segment is driven by rise in prevalence and incidence of ovarian cancer and head & neck squamous cell carcinoma. The non-small cell lung cancer (NSCLC) segment accounted for a significant share of the market in 2020. The segment is likely to grow at rapid pace during the forecast period. NSCLC is the most common type of lung cancer, accounting for 80% to 85% of lung cancer diagnoses. The exposure to hazardous material, smoking, air pollution, family history of lung cancer, etc. are risk factors associated with NSCLC.
• North America dominated the global oncolytic virus immunotherapy market in 2020. The trend is anticipated to continue during the forecast period. Strategies adopted by key players, such as product approval & launch and mergers & acquisitions, well-established healthcare infrastructure, and early adoption of advanced therapeutics drive the oncolytic virus immunotherapy market in the region. Moreover, the availability of IMLYGIC in the U.S. is expected to boost the growth of market in North America.
• Asia Pacific accounted for a significant share of the global oncolytic virus immunotherapy market in 2020. The market in the region is likely to expand at a moderate CAGR during the forecast period. Government initiatives in modernization of healthcare infrastructure in developing countries and rise in awareness about advanced therapeutics are key factors projected to propel the oncolytic virus immunotherapy market in Asia Pacific.

Competition Landscape

The global oncolytic virus immunotherapy market is fragmented in terms of number of players. Key players in the global oncolytic virus immunotherapy market include Amgen, Inc., Merck & Co., Inc. (Viralytics Limited), Shanghai Sunway Biotech Co., Ltd., TILT Biotherapeutics, Oncorus, Inc., Replimune Group, Inc., Oncolys BioPharma, Inc., Sorrento Therapeutics, Inc., Oncolytics Biotech, Inc., and SillaJen, Inc.

Market Segmentation

By Type 

• Herpes Simplex Virus
• Vaccinia Virus
• Adenovirus
• Reovirus
• Others

By Route of Administration

• Intratumoral
• Intravenous

By Application

• Melanoma
• Non-small Cell Lung Cancer (NSCLC)
• Pancreatic Cancer
• Breast Cancer
• Others

By Region

• North America
• Europe
• Asia Pacific          
• Rest of the World

Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/38191

You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333

Blog: https://www.novaoneadvisor.com/

Blog: https://qyresearchmedical.com/